Pulsenmore Ltd. Ordinary Shares
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Elazar Sonnenschein
- Full Time Employees
- 71
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 8 Omarim Street Omer HD Israel 8496500
- IPO Date
- Jan 21, 2026
- CIK
- 0002064764
- Website
- pulsenmore.com
- Similar Companies
- Business
- Pulsenmore Ltd. is an Israel-based medical technology company that develops, manufactures, and markets portable home ultrasound solutions for remote patient examination and telehealth-enabled monitoring, with products designed for obstetric and fertility-related applications. Headquartered in Israel, the company focuses on bringing ultrasound imaging into the home through compact devices, cloud-based image handling, and clinician-reviewed platforms. Main products and services - Pulsenmore ES: a handheld home ultrasound system designed for prenatal imaging and remote monitoring, including a compact ultrasound unit, cradle/docking, smartphone integration, and cloud-based image uploading for clinician review. - Pulsenmore FC: a self-test ultrasound platform for monitoring follicle size in women undergoing fertility treatments, comprising a miniaturized ultrasound device paired with patient-facing software and clinician oversight. - Telehealth-enabled imaging services: cloud storage, secure data transmission, clinician dashboards for remote interpretation, and telemedicine workflows that support remote diagnosis and monitoring. - Hardware and software integration: portable ultrasound hardware with smartphone/app interfaces and cloud-based data management to enable remote follow-up and documentation. Latest major company changes - Strategic expansion into home-use ultrasound markets with ongoing commercialization of Pulsenmore ES in multiple regions; continues to advance regulatory approvals and market deployments. - Initiation or expansion of collaboration efforts to integrate telehealth capabilities with existing healthcare systems, reflecting a broader push into remote diagnostic workflows. - Ongoing commercial activity around Pulsenmore FC, targeting fertility clinics and patients in Israel with continued product refinement and regulatory updates to support broader adoption. Industry context and markets - Industry: medical devices, focused on point-of-care and home-based imaging technologies; telehealth-enabled diagnostic solutions. - Business segments: home ultrasound devices for obstetrics and fertility monitoring; related software as a service for data management and clinician review; telehealth integrations. - Target markets: healthcare providers, fertility clinics, obstetric care settings, and patients seeking remote diagnostic options; global deployment with emphasis on Israel and other international markets. - Geographic operations: headquarters in Israel; products marketed and sold worldwide, with regulatory considerations in multiple jurisdictions. Founding information and corporate relationships - Founding year: 2014. - Headquarters: Israel. - Corporate relationships: operates as an independent medical device company; engages in partnerships and collaborations to expand telehealth-enabled imaging solutions (exact parent/sibling structures are not specified in the provided data).
Company News
Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026
Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026
Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring
Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program
Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor
Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States
Pulsenmore Announces Full Year 2025 Financial Results and Webcast
Pulsenmore Announces Full Year 2025 Earnings Conference Call
Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.